Subsequent Events	3 Months Ended
Mar. 31, 2025
Subsequent Events
Subsequent Events	Note 18. Subsequent Events As discussed in Note 11, Common Stock Financing Activities, in connection with the March 2025 issuance and sale in a public offering of (i) 188 shares of the Company’s common stock, (ii) pre-funded warrants to purchase 3,812 shares of Common Stock, and (iii) accompanying warrants to purchase 4,000 shares of Common Stock, after March 31, 2025 but before financial statement issuance, certain investors exercised 300 pre-funded warrants to purchase 300 shares of Common Stock. As discussed in Note 9, Debt and Credit Facilities, in connection with the Fifth Amendment of the Credit Agreement and issuance of new warrants to the Lenders to purchase an aggregate of 313 shares of common stock, after March 31, 2025 but before financial statement issuance, the Company issued 284 shares of Common Stock in connection with the cashless exercises of 313 warrants. On April 3, 2025, the Company entered into an Equity Distribution Agreement (the “Equity Distribution Agreement”) with Canaccord Genuity LLC (“Canaccord”) to sell shares of the Company’s common stock, par value $0.001 per share, with aggregate gross sales proceeds of up to $8,135, from time to time, through an “at the market” equity offering program under which Canaccord will act as sales agent. On April 8, 2025, the Board unanimously approved (i) the payment of a retention bonus to all non-executive employees in the total aggregate amount of $1,545, to be paid in two equal installments and (ii) the issuance of 66 RSUs which fully vest on the one-year anniversary of the grant date. The first installment of the retention bonus was paid on April 30, 2025 and the second installment shall be paid upon successful completion of the Serenity Trial data readout and securing additional financing. Each such installment payment is subject to the applicable employee’s continued employment through December 31, 2025.

Subsequent Events

3 Months Ended

Mar. 31, 2025

Note 18. Subsequent Events

As discussed in Note 11, Common Stock Financing Activities, in connection with the March 2025 issuance and sale in a public offering of (i) 188 shares of the Company’s common stock, (ii) pre-funded warrants to purchase 3,812 shares of Common Stock, and (iii) accompanying warrants to purchase 4,000 shares of Common Stock, after March 31, 2025 but before financial statement issuance, certain investors exercised 300 pre-funded warrants to purchase 300 shares of Common Stock.

As discussed in Note 9, Debt and Credit Facilities, in connection with the Fifth Amendment of the Credit Agreement and issuance of new warrants to the Lenders to purchase an aggregate of 313 shares of common stock, after March 31, 2025 but before financial statement issuance, the Company issued 284 shares of Common Stock in connection with the cashless exercises of 313 warrants.

On April 3, 2025, the Company entered into an Equity Distribution Agreement (the “Equity Distribution Agreement”) with Canaccord Genuity LLC (“Canaccord”) to sell shares of the Company’s common stock, par value $0.001 per share, with aggregate gross sales proceeds of up to $8,135, from time to time, through an “at the market” equity offering program under which Canaccord will act as sales agent.

On April 8, 2025, the Board unanimously approved (i) the payment of a retention bonus to all non-executive employees in the total aggregate amount of $1,545, to be paid in two equal installments and (ii) the issuance of 66 RSUs which fully vest on the one-year anniversary of the grant date. The first installment of the retention bonus was paid on April 30, 2025 and the second installment shall be paid upon successful completion of the Serenity Trial data readout and securing additional financing. Each such installment payment is subject to the applicable employee’s continued employment through December 31, 2025.